Free Trial
NASDAQ:DRUG

Bright Minds Biosciences Q1 2025 Earnings Report

Bright Minds Biosciences logo
$39.05 +0.25 (+0.64%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bright Minds Biosciences EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Bright Minds Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bright Minds Biosciences Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Friday, February 14, 2025
Conference Call Time
4:00PM ET

Earnings Documents

Bright Minds Biosciences Earnings Headlines

Bright Minds Biosciences to Present at Upcoming Conferences
New Banking Law #1582 Could Unlock $21 Trillion for Americans
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Equities Analysts Issue Forecasts for DRUG FY2025 Earnings
See More Bright Minds Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email.

About Bright Minds Biosciences

Bright Minds Biosciences (NASDAQ:DRUG), a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

View Bright Minds Biosciences Profile

More Earnings Resources from MarketBeat